Organovo is an early stage biotechnology company with a focus on building high fidelity, 3D tissues that epitomize key aspects of human disease. Using these models to identify gene targets that are responsible for disease growth, Organovo plans to initiate drug discovery programs around those validated targets. Their initial focus is on the intestines and currently have ongoing development efforts in ulcerative colitis (“UC”) and Crohn’s disease (“CD”) for 3D tissues. The company's proprietary technology mirrors key aspects of human tissue composition, structure, functionality and disease. Some key advancements so far by Organovo include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures.